So ThyroPredict is an assay which we have developed at HCG...
So ThyroPredict is an assay which we have developed at HCG. This was initially a DNB, Surgical Oncology Residence Thesis, where we decided to really come to a conclusion where Bethesda 3 and 4 patients can be observed or need surgery. Now this confusion is world over. This is a world over confusion for Bethesda 3 and 4 patients. When they come to the clinic, they ask their doctor whether I should undergo surgery or not. And if I don’t want to undergo surgery, are there any options? And the predictability of having cancer is the driving force. And Bethesда 3 says that around 15 % is the possibility of having Cancer, while BethesDA 4 around 25 to 30 percent chances of having can now whether this percentage can be tweaked to say 90 to 99 % and 1 % or not, that was the question. And in the Western world there are some tests like Thyrosic and Afirma which can give these solutions, but they are very costly tests and in a country like India, we can’t afford this. So we wanted to develop something specific to our country. What we did that So we first researched that whether FNSE slides, if we can draw out the material which is significant for molecular assay. So we validated it and we could do it. Now the second phase was this study where what we did that all Bethesda 3 and 4 patients who were to undergo surgery, their slides were blinded for this study and they were operated. So on one side we knew what is the final histopathology report and the other side we know what ThyroPredict predicted and this was blinded. So when we analyzed the final Histopathology Report, we could conclude that what are the sensitivity and specificity of this test. And we could realize that it is more of a ruling test. The positive predictive value was 100 % in our study. So that is one thing which was very good. Second thing is that we could compete for sensitivity to the other tests which are run in international platforms. Now the crux of the matter is that the cost is extremely low. It’s around $500 for a single test. So that’s the advantage for the third world countries. For the countries where resources are limited, this can provide a value-added conclusion for Bethesda 3 and 4 patients. the patient is convinced that this is a cancer, they will not wait. But when there is a confusion, whether what is the possibility of this indeterminate nodule having cancer, that is where this battle in their mind starts. So these molecular tests gives you more than 90 % confirmation whether this inddeterminate nodules is going to be cancer or not cancer. So that solidifies their judgment for waiting, not doing surgery, and following it up. is a very initial study. This is a single center study. So we need to do it as multicentric study. We need to validate it through other centers. in a larger scale And then probably we will be able to recommend it on a larger skill.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.